These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 1633400)
1. Diagnosis of fatty liver with MR imaging. Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400 [TBL] [Abstract][Full Text] [Related]
2. Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents. Kreft BP; Tanimoto A; Baba Y; Zhao L; Finn JP; Stark DD J Magn Reson Imaging; 1994; 4(3):337-42. PubMed ID: 8061431 [TBL] [Abstract][Full Text] [Related]
3. [Magnetic resonance imaging of the liver: what kind of contrast agents?]. De Gaspari A; De Cobelli F; Del Maschio A Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451 [TBL] [Abstract][Full Text] [Related]
4. Liver-specific contrast agents for MRI. Stark DD; Elizondo G; Fretz CJ Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535 [No Abstract] [Full Text] [Related]
5. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver. Tanimoto A; Kuribayashi S Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of liver contrast agents: impact for clinical use. Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397 [TBL] [Abstract][Full Text] [Related]
7. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging. Kim YK; Kim CS; Kwak HS; Lee JM J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325 [TBL] [Abstract][Full Text] [Related]
8. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings. Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of superparamagnetic iron oxide for MR imaging of liver injury: proton relaxation mechanisms and optimal MR imaging parameters. Tanimoto A; Mukai M; Kuribayashi S Magn Reson Med Sci; 2006 Jul; 5(2):89-98. PubMed ID: 17008765 [TBL] [Abstract][Full Text] [Related]
10. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034 [TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced MR imaging of the liver. Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. Tanimoto A; Kreft BP; Baba Y; Zhao L; Finn JP; Compton CC; Stark DD J Magn Reson Imaging; 1993; 3(5):786-93. PubMed ID: 8400566 [TBL] [Abstract][Full Text] [Related]
14. Ex-vivo MR imaging of liver intracellular contrast agents. Mascalchi M; Jin XN; Agen C; Petruzzi P; Nardini D; Tessa C; Caramella D; Bartolozzi C Magn Reson Imaging; 1997; 15(4):469-74. PubMed ID: 9223047 [TBL] [Abstract][Full Text] [Related]
15. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518 [TBL] [Abstract][Full Text] [Related]
16. Nondiffuse fatty change of the liver: discerning pseudotumor on MR images enhanced with ferumoxides-initial observations. Hirohashi S; Ueda K; Uchida H; Ono W; Takahama J; Takewa M; Kitano S; Ohishi H Radiology; 2000 Nov; 217(2):415-20. PubMed ID: 11058637 [TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging of experimental inflammatory bowel disease: quantitative and qualitative analyses with histopathologic correlation in a rat model using the ultrasmall iron oxide SHU 555 C. Frericks BB; Wacker F; Loddenkemper C; Valdeig S; Hotz B; Wolf KJ; Misselwitz B; Kühl A; Hoffmann JC Invest Radiol; 2009 Jan; 44(1):23-30. PubMed ID: 18836385 [TBL] [Abstract][Full Text] [Related]
18. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents. Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202 [TBL] [Abstract][Full Text] [Related]
19. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images. Marin D; Iannaccone R; Catalano C; Passariello R J Magn Reson Imaging; 2006 Sep; 24(3):690-4. PubMed ID: 16878304 [TBL] [Abstract][Full Text] [Related]
20. Value of dual contrast liver MRI at 3.0 T in differentiating well-differentiated hepatocellular carcinomas from dysplastic nodules: preliminary results of multivariate analysis. Yoon MA; Kim SH; Park HS; Lee DH; Lee JY; Han JK; Choi BI Invest Radiol; 2009 Oct; 44(10):641-9. PubMed ID: 19724237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]